

This educational activity is supported by a grant from Bristol-Myers Squibb.

A satellite symposium in association with the
1st European Myeloma Network (EMN) Meeting.



Treatment Decisions for Relapsed/Refractory Multiple Myeloma:

Fitting the Pieces Together

Friday, 20 April 2018
14.30 – 16.00

Auditorium Agnelli
Lingotto Conference Center
Via Nizza, 280
Turin, Italy



EU Office
prIME Oncology
Schenkkade 50, Suite 16
2595 AR The Hague
the Netherlands
tel +31.70.3067.190

US Office
prIME Oncology
5901-C Peachtree Dunwoody Road NE, Suite 250
Atlanta, Georgia 30328
United States
tel +1.678.892.1340


About prIME Oncology

prIME Oncology is a global professional Independent Medical Education organization specializing in educational activities for physicians who treat patients with cancer.

With the ultimate goal of improving patient outcomes, prIME Oncology provides evidence-based, state-of-the-art educational activities that assist oncology clinicians in making up-to-date and appropriate treatment decisions.

prIMEoncology.org

©2018 prIME Oncology
PI8LSS036



Treatment Decisions for Relapsed/Refractory Multiple Myeloma:



Fitting the Pieces Together

Activity Overview

Enhance your understanding of the treatment of patients with relapsed/refractory multiple myeloma (R/R MM) with a focus on immunotherapy along with treatment selection and sequencing in the R/R disease setting. In addition to a short didactic lecture on the evolving role of immunotherapy in multiple myeloma, real-life clinical scenarios in the R/R setting will be presented and examined during a faculty panel discussion.

Target Audience

This activity is intended for hematologists, oncologists, and other healthcare professionals involved in the management of patients with MM.

Learning Objectives

After successful completion of this educational activity, participants should be able to:

- Discuss the rationale and mechanism of action for emerging immunotherapy options in the treatment of relapsed/refractory multiple myeloma (R/R MM)
- Evaluate recent clinical trial data investigating the efficacy and safety of novel doublet and triplet regimens and employ best practices in the selection of these regimens in the treatment of R/R MM
- Describe the factors that influence treatment selection and sequencing in the R/R disease setting
- Identify important ongoing clinical trials investigating novel treatment approaches for R/R MM



Continuing Medical Education

prIME Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

prIME Oncology designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Sunshine Act/EFPIA Disclosure Code

prIME Oncology complies with all Sunshine Act reporting requirements as outlined by CMS and applicable manufacturers and with EFPIA Disclosure Code reporting requirements.



Chair

Pieter Sonneveld, MD, PhD
Erasmus Medical Center
Cancer Institute
Rotterdam, the Netherlands

Faculty

Meletios Dimopoulos, MD
University of Athens
Athens, Greece

Hermann Einsele, MD
Julius Maximilian University
of Würzburg
Würzburg, Germany

Gareth Morgan, MD, PhD, FRCP, FRCPath
University of Arkansas for
Medical Sciences
Little Rock, Arkansas,
United States

Agenda

- 14.30 Welcome and introduction
Pieter Sonneveld, MD, PhD
- 14.35 Pop quiz on R/R MM
Pieter Sonneveld, MD, PhD
- 14.40 Hot topic in MM: The evolving role for immunotherapy in patients with R/R disease
Gareth Morgan, MD, PhD, FRCP, FRCPath
- 14.55 Questions from the audience
- 15.00 Weighing the options at first relapse
Hermann Einsele, MD
- 15.15 Questions from the audience
- 15.20 How do I choose? Treatment decisions after multiple lines of therapy
Meletios Dimopoulos, MD
- 15.35 Questions from the audience
- 15.40 Burning questions and future directions in R/R MM: A panel discussion with the experts
Moderator: Pieter Sonneveld, MD, PhD
- 15.55 Post-activity quiz and prIME Points[™]
Pieter Sonneveld, MD, PhD
- 16.00 Adjourn

